Trade

with

Oncothyreon Inc
(NASDAQ: ONTY)
AdChoices
1.84
+0.07
+3.95%
After Hours :
1.84
+0.00
+0.01%

Open

1.79

Previous Close

1.77

Volume (Avg)

891.37k (761.72k)

Day's Range

1.78-1.85

52Wk Range

1.67-4.08

Market Cap.

130.29M

Dividend Rate ( Yield )

-

Beta

1.12

Shares Outstanding

70.81M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 0

    • Net Income

    • -38.76M

    • Market Cap.

    • 130.29M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.12

    • Forward P/E

    • -4.56

    • Price/Sales

    • -

    • Price/Book Value

    • 2.28

    • Price/Cash flow

    • -4.94

      • EBITDA

      • -38.27M

      • Return on Capital %

      • -42.93

      • Return on Equity %

      • -47.27

      • Return on Assets %

      • -42.93

      • Book Value/Share

      • 0.81

      • Shares Outstanding

      • 70.81M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 3.67

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -0.38

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 82.75

            • Pre-Tax Margin

            • -

            • 39.38

            • Net Profit Margin

            • -

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 13.70

              • 2.92

              • Quick Ratio

              • 13.60

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.11

              • 2.21

              • Book Value/Share

              • 0.81

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -4.40

                • 243.90

                • P/E Ratio 5-Year High

                • -26.82

                • 634.30

                • P/E Ratio 5-Year Low

                • -3.59

                • 124.82

                • Price/Sales Ratio

                • -

                • 9.29

                • Price/Book Value

                • 2.35

                • 8.39

                • Price/Cash Flow Ratio

                • -4.94

                • 49.75

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -47.27

                    (-72.90)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -42.93

                    (-45.70)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -47.27

                    (-69.40)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • -

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -41.22M
                  Operating Margin
                  -
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -4.94
                  Ownership

                  Institutional Ownership

                  56.35%

                  Top 10 Institutions

                  43.37%

                  Mutual Fund Ownership

                  17.63%

                  Float

                  86.94%

                  5% / Insider Ownership

                  7.01%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Franklin Biotechnology Discovery

                  •  

                    3,063,600

                  • 116.05

                  • 4.33

                  • Franklin Biotechnology Discovery Fund

                  •  

                    1,413,000

                  • 0.00

                  • 2.00

                  • iShares Russell 2000 (AU)

                  •  

                    1,226,062

                  • -1.81

                  • 1.60

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,167,603

                  • 2.86

                  • 1.65

                  • Vanguard Extended Market Index Fund

                  •  

                    687,147

                  • 8.20

                  • 0.97

                  • Candriam Eqs L Biotechnology

                  •  

                    580,000

                  • 0.00

                  • 0.82

                  • iShares Russell 2000 Growth

                  •  

                    562,653

                  • -1.57

                  • 0.73

                  • Fidelity® Select Pharmaceuticals Port

                  •  

                    324,000

                  • 0.00

                  • 0.46

                  • Driehaus Micro Cap Growth Fund

                  •  

                    268,293

                  • 1.03

                  • 0.38

                  • VAM Funds (Lux) – US Micro Cap Growth

                  •  

                    232,991

                  • 1.70

                  • 0.33

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Bvf Inc

                  •  

                    9,858,278

                  • +9.51%

                  • 13.92

                  • Qvt Financial LP

                  •  

                    5,628,899

                  • 0.00%

                  • 7.95

                  • Franklin Advisers, Inc.

                  •  

                    4,476,600

                  • +5.17%

                  • 6.32

                  • BlackRock Fund Advisors

                  •  

                    2,826,828

                  • +22.04%

                  • 3.99

                  • Arnhold & S. Bleichroeder Advisers, LLC

                  •  

                    2,384,039

                  • -12.51%

                  • 3.37

                  • Vanguard Group, Inc.

                  •  

                    1,915,113

                  • +8.53%

                  • 2.70

                  • D. E. Shaw & Co LP

                  •  

                    991,900

                  • +36.62%

                  • 1.40

                  • Adage Capital Partners Gp LLC

                  •  

                    950,000

                  • 0.00%

                  • 1.34

                  • Employees Retirement System Of Texas

                  •  

                    891,000

                  • 0.00%

                  • 1.26

                  • Great Point Partners LLC

                  •  

                    791,800

                  • -20.17%

                  • 1.12

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Value

                  Oncothyreon Inc was incorporated on September 7, 2007. The Company is a clinical-stage biopharmaceutical company that develops therapeutic products for the treatment of cancer. Its cancer vaccines are designed to stimulate the immune...more system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. The Company's cancer vaccine product candidate, tecemotide, formerly known as L-BLP25 or Stimuvax, is being evaluated for the treatment of non-small cell lung cancer, or NSCLC. It has granted license to Merck KGaA of Darmstadt, Germany, or Merck KGaA, for the development, manufacture and commercialization of tecemotide. The Company is also conducting Phase 1 trial for ONT-10, a cancer vaccine. The Company's pipeline of products incl...moreudes immunotherapies and small molecules. The Company currently outsources the manufacturing of drug substances and drug products for all of its products in clinical development. As of December 31, 2013 the Company owned approximately 25 U.S. patents and patent applications. It competes with pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations which are developing various approaches to cancer therapy. In addition to regulations in the United States, the Company will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its product candidates.lessless

                  Key People

                  Dr. Robert L. Kirkman, M.D.

                  CEO/Director/President

                  Dr. Christopher S. Henney, PhD

                  Chairman of the Board/Director

                  Ms. Julie M. Eastland

                  CFO/Chief Accounting Officer/Secretary/Vice President, Divisional

                  Dr. Scott Peterson,PhD

                  Chief Scientific Officer/Vice President, Divisional

                  Dr. Diana Hausman

                  Chief Medical Officer/Vice President, Divisional

                  • Oncothyreon Inc

                  • 2601 Fourth Avenue

                  • Seattle, WA 98121

                  • USA.Map

                  • Phone: +1 206 801-2100

                  • Fax: +1 206 801-2101

                  • oncothyreon.com

                  Incorporated

                  2007

                  Employees

                  43

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: